Exhibit 99.1



Xtant Medical Announces Second Quarter 2020 Financial Results


BELGRADE, MT, August 3, 2020 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2020.


Second Quarter 2020 Financial Highlights:


Revenue for the second quarter of 2020 was $10.5 million, compared to $15.3 million for the prior-year period
Operating expenses in the second quarter of 2020 were $6.9 million, compared to $10.5 million for the prior-year period
Net loss incurred in the second quarter of 2020 was $2.5 million, compared to a net loss of $1.9 million for the prior-year period
Adjusted EBITDA for the second quarter of 2020 was $0.7 million, compared to $1.1 million for the prior-year period


“We are pleased with our second-quarter revenue performance primarily reflecting a rebound in spinal elective procedure volumes in June following sharp declines at the start of the COVID-19 pandemic,” said Sean Browne, President and CEO. “Our early actions to reduce expenses enabled us to conserve cash and rightsize our cost structure during this uncertain environment. Going forward, we believe operating as a leaner organization and improving our overall efficiencies will allow us to live our mission of ‘honoring the gift of donation, so our patients can live as full a life as possible.’”


COVID-19 Response Update


As previously announced, Xtant Medical identified four areas to maintain business continuity and emerge from the COVID-19 pandemic in a position of strength. We are committed to 1) Keeping our employees safe and healthy, (2) Conserving Cash, (3) Optimizing our production and thereby improving our inventory position, and (4) Improve our overall operational efficiency.


Second Quarter 2020 Financial Results


Total revenue for the three months ended June 30, 2020 was $10.5 million, which represents a decrease of 31.1% compared to $15.3 million in the same quarter of the prior year. The decrease in revenue is attributed primarily to the impact of COVID-19 and the sudden drop in elective procedures beginning in early March as result of the pandemic. Management anticipates that the current pandemic will impact revenue for the remainder of 2020.


Gross margin for the second quarter of 2020 was 62.2%, compared to 64.9% for the same period in 2019.


Operating expenses for the second quarter of 2020 were $6.9 million, compared to $10.5 million for the second quarter of 2019. The decrease was primarily due to a reduction in sales commissions, reduced salaries and wages, lower legal and consulting fees, reduced executive recruiting fees, and reduced legal settlement expenses, partially offset by additional stock-based compensation expense during the current year period.


Second quarter 2020 net loss was $2.5 million, or $0.19 per share, compared to second quarter 2019 net loss of $1.9 million, or $0.15 per share.





Adjusted EBITDA for the second quarter of 2020 was $0.7 million compared to $1.1 million for the same period in 2019. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash special charges, provision for losses on inventory and accounts receivable, non-cash compensation, change in warrant derivative liability, separation related expenses, and litigation settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.


Conference Call


Xtant Medical will host a webcast and conference call to discuss the second quarter 2020 financial results on Monday, August 3, 2020 at 4:30 PM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”


About Xtant Medical Holdings, Inc.


Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.


The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.


Non-GAAP Financial Measures


To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.





Cautionary Statement Regarding Forward-looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations that by operating as a leaner organization and improving its overall efficiencies it will be well-positioned to manage near-term challenges and that the current pandemic will impact revenue for the remainder of 2020. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risks and uncertainities surrounding the debt restructuring transactions, including without limitation, the Company’s ability to consummate the restructuring transactions and to do so on a timely basis and its ability to maintain the listing of its common stock on the NYSE American; effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the effect of management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) on March 5, 2020 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.


Investor Relations Contact


David Carey

Lazar FINN

Ph: 212-867-1762

Email: dcarey@finnpartners.com







(In thousands, except number of shares and par value)



As of June 30,


   As of December 31, 2019 
Current Assets:          
Cash and cash equivalents  $3,019   $5,237 
Trade accounts receivable, net of allowance for credit losses of $728 and doubtful accounts of $500, respectively   7,583    10,124 
Inventories   19,888    16,101 
Prepaid and other current assets   899    784 
Total current assets   31,389    32,246 
Property and equipment, net   4,256    4,695 
Right-of -use asset, net   1,898    2,100 
Goodwill   3,205    3,205 
Intangible assets, net   486    515 
Other assets   432    394 
Total Assets  $41,666   $43,155 
Current Liabilities:          
Accounts payable  $3,072   $2,188 
Accrued liabilities   5,894    6,632 
Current portion of lease liability   408    394 
Current portion of financing lease obligations   101    176 
Total current liabilities   9,475    9,390 
Long-term Liabilities:          
Lease liability, less current portion   1,518    1,726 
Long-term debt, plus premium and less issuance costs   77,531    76,244 
Total Liabilities   88,524    87,360 
Stockholders’ Equity (Deficit)          
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, $0.000001 par value; 75,000,000 shares authorized; 13,223,565 shares issued and outstanding as of June 30, 2020 and 13,161,762 shares issued and outstanding as of December 31, 2019   -    - 
Additional paid-in capital   181,412    179,061 
Accumulated deficit   (228,270)   (223,266)
Total Stockholders’ Equity (Deficit)   (46,858)   (44,205)
Total Liabilities & Stockholders’ Equity (Deficit)  $41,666   $43,155 







(Unaudited, in thousands, except number of shares and per share amounts)



Three Months Ended June 30,

   Six Months Ended June 30, 
   2020   2019   2020   2019 
Orthopedic product sales  $10,493   $15,197   $25,227   $31,883 
Other revenue   36    74    80    114 
Total revenue   10,529    15,271    25,307    31,997 
Cost of sales   3,979    5,365    9,144    11,278 
Gross profit   6,550    9,906    16,163    20,719 
Gross profit %   62.2%   64.9%   63.9%   64.8%
Operating expenses                    
General and administrative   2,931    4,187    7,250    8,664 
Sales and marketing   3,895    6,072    10,309    12,814 
Research and development   111    210    353    472 
Total operating expenses   6,937    10,469    17,912    21,950 
Loss from operations   (387)   (563)   (1,749)   (1,231)
Other (expense) income                    
Interest expense   (2,054)   (1,301)   (3,163)   (3,319)
Other (expense) income   -    (53)   -    (143)
Total Other (Expense)   (2,054)   (1,354)   (3,163)   (3,462)
Net Loss Before Provision for Income Taxes   (2,441)   (1,917)   (4,912)   (4,693)
Provision for income taxes                    
Current and deferred   (23)   (22)   (45)   (45)
Net Loss  $(2,464)  $(1,939)  $(4,957)  $(4,738)
Net loss per share:                    
Basic  $(0.19)  $(0.15)  $(0.38)  $(0.36)
Dilutive  $(0.19)  $(0.15)  $(0.38)  $(0.36)
Shares used in the computation:                    
Basic   13,223,565    13,161,762    13,199,455    13,166,136 
Dilutive   13,223,565    13,161,762    13,199,455    13,166,136 







(Unaudited, in thousands)


   Six Months Ended June 30, 
   2020   2019 
Operating activities:          
Net loss  $(4,957)  $(4,738)
Adjustments to reconcile net loss to net cash provided by operating activities:           
Depreciation and amortization    1,153    1,559 
(Gain) loss on disposal of fixed assets   (118)   92 
Non-cash interest    3,149    3,272 
Non-cash rent expense   8    11 
Stock-based compensation    489    161 
Provision for reserve on accounts receivable    204    232 
Provision for excess and obsolete inventory   377    518 
Changes in operating assets and liabilities:           
Accounts receivable    2,290    1,403 
Inventories    (4,164)   955 
Prepaid and other assets    (153)   242 
Accounts payable    884    (3,481)
Accrued liabilities    (738)   728 
Net cash (used in) provided by operating activities    (1,576)   954 
Investing activities:          
Purchases of property and equipment    (673)   (211)
Proceeds from sale of fixed assets    106    163 
Net cash used in investing activities    (567)   (48)
Financing activities:          
Payments on financing leases    (75)   (277)
Costs associated with Second Amended and Restated Credit Agreement    -    (108)
Net cash used in financing activities    (75)   (385)
Net change in cash and cash equivalents    (2,218)   521 
Cash and cash equivalents at beginning of period    5,237    6,797 
Cash and cash equivalents at end of period   $3,019   $7,318 







(Unaudited, in thousands)


   Three Months Ended June 30,   Six Months Ended June 30, 
   2020   2019   2020   2019 
Net Loss  $(2,464)  $(1,939)  $(4,957)  $(4,738)
Other expense   1    56    6    131 
Depreciation and amortization   468    783    1,153    1,559 
Interest expense   2,054    1,301    3,163    3,319 
Tax expense   23    22    45    45 
Non-GAAP EBITDA   82    223    (590)   316 
Non-GAAP EBITDA/Total revenue   0.8%   1.5%   -2.3%   1.0%
Provision for losses on accounts receivable   66    138    204    232 
Provision for excess and obsolete inventory   346    365    377    518 
Non-cash compensation   219    39    489    161 
Change in warrant derivative liability   (1)   (3)   (7)   12 
Separation-related expenses   -    (15)   749    (37)
Field action expenses   -    125    -    125 
Litigation reserve   -    270    -    800 
Non-GAAP Adjusted EBITDA  $712   $1,142   $1,222   $2,127 
Non-GAAP Adjusted EBITDA/Total revenue   6.8%   7.5%   4.8%   6.6%



The following information was filed by Xtant Medical Holdings, Inc. (XTNT) on Monday, August 3, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Xtant Medical Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Xtant Medical Holdings, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account